Skip to content
value.today
Fortress Biotech, Inc. logo

Fortress Biotech, Inc.

FBIO
$74 Mmarket cap on Oct 30, 2026+59.9% since Jan 2024
Compare
World rank
#19,888
Revenue
$63 M
For year ending December-2025
Net income
$7 M
10.8% margin
SEC filing
Employees
34
2016
Wikidata

Fortress Biotech, Inc. in brief

Fortress Biotech, Inc. is a listed company in the Biotechnology industry, based in California, USA. It was founded in 2006. Its market value was $74 M on 30 October 2026, which makes it the 19,888th largest listed company in the world and the 3,688th largest in the USA on this site. In the year to December 2025 it had sales of $63 M and a net profit of $7 M, about 11 cents of profit for every dollar of sales. It employs about 34 people and Lindsay A. Rosenwald is its chief executive. Its largest product and service lines by sales in 2025 were Qbrexza (40%), Emrosi (23%) and Accutane (20%). Its shares trade under the symbol FBIO (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Fortress Biotech, Inc.

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Fortress Biotech, Inc. timeline

5 events, 2006–2025
  1. 2006
  2. 🏁
    · approximate
    Founded
  3. 2008
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2015
  6. ✎
    Renamed Fortress Biotech, Inc.
    Formerly Coronado Biosciences Inc.
  7. 2023
  8. 💰
    Record revenue of $85 million
    FY2023, the highest of the 8 years on record.
  9. 2025
  10. 💰
    Record net income of $37 million
    FY2025, the highest profit of the 4 years on record.

Events of Fortress Biotech, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$86 M$173 M$259 M$346 M2020202120222023202420252026

World rank over time

▼ down 3,815 places since 2020
2020-01-01: #16121#16,12120202021-01-01: #13378#13,37820212022-01-07: #17933#17,93320222022-12-25: #24263#24,26320222023-07-30: #23235#23,23520232024-01-05: #25343#25,34320242026-03-08: #9905#9,90520262026-08-01: #17460#17,46020262026-10-14: #20111#20,11120262026-10-30: #19936#19,9362026

Rank in USA: #3,277 (Jan 2020) · #2,898 (Jan 2021) · #3,677 (Jan 2022) · #4,653 (Dec 2022) · #4,470 (Jul 2023) · #4,110 (Jan 2024) · #1,926 (Mar 2026) · #3,437 (Aug 2026) · #3,715 (Oct 2026) · #3,692 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
0.7×
Price / sales (TTM)
1.1×
Price / book
1.5×
Free cash flow yield
-109.0%
Net margin (TTM)
163.3%
Operating margin
-111.0%
Return on equity
224.2%
Liabilities / assets
66.5%
Net debt
$-25M
Revenue growth
+9.7%
R&D / revenue
18.8%
Revenue per employee
$1.9 M
Profit per employee
$201 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $27M, net income $-84M$27MFY18Fiscal year ending Dec 2019: revenue $37M, net income $-40M$37MFY19Fiscal year ending Dec 2020: revenue $46M, net income $-47M$46MFY20Fiscal year ending Dec 2021: revenue $69M, net income $-65M$69MFY21Fiscal year ending Dec 2022: revenue $76M, net income $-87M$76MFY22Fiscal year ending Dec 2023: revenue $85M, net income $-61M$85MFY23Fiscal year ending Dec 2024: revenue $58M, net income $-46M$58MFY24Fiscal year ending Dec 2025: revenue $63M, net income $7M$63MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$63M+9.7%$-70M$7M10.8%
Dec 2024$58M-31.7%$-110M$-46M-79.8%
Dec 2023$85M+11.6%$-142M$-61M-71.8%
Dec 2022$76M+10.1%$-204M$-87M-114.3%
Dec 2021$69M+50.9%$-189M$-65M-94.1%
Dec 2020$46M+24.5%$-94M$-47M-102.0%
Dec 2019$37M+36.3%$-111M$-40M-109.1%
Dec 2018$27M—$-120M$-84M-313.1%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-66M——$-0.07—
Dec 2024$-80M$0M$-80M$-2.69—
Dec 2023$-128M$0M$-128M$-8.47—
Dec 2022$-179M$3M$-182M$-15.97—
Dec 2021$-117M$5M$-121M$-0.79—
Dec 2020$-84M$2M$-86M$-0.65—
Dec 2019$-95M$2M$-97M$-0.73—
Dec 2018$-99M$7M$-106M$-1.94—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$68M
Net income, trailing 12 months
$112M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $15M, net income $-7M$15MDec ’24Three months to Mar 2025: revenue $13M, net income $-11M$13MMar ’25Three months to Jun 2025: revenue $16M, net income $15M$16MJun ’25Three months to Sep 2025: revenue $18M, net income $6M$18MSep ’25Three months to Dec 2025 (from the annual report): revenue $16M, net income $-4M$16MDec ’25Three months to Mar 2026: revenue $16M, net income $110M$16MMar ’26Three months to Jun 2026: revenue $19M, net income $-0M$19MJun ’26Three months to Sep 2026: revenue $19M, net income $-6M$19MSep ’26

Latest quarter to Sep 2026: revenue $19M (+8.7% on a year earlier), net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Fortress Biotech, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$63 M
Operating income
$-70 M
Net income
$7 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$186 M
Total liabilities
$123 M
Total equity
$50 M

As of December-2025

Top 60 institutional investors in Fortress Biotech, Inc.#

As of Sep 30, 2026
60 institutions held 8.3 M shares (about 22.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 16.8%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Fortress Biotech, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Millennium Management LLC2,165,401New5.89%$5 MNov 16, 2026
2Vanguard Capital Management LLC1,037,2030 (0.00%)2.82%$2 MNov 13, 2026
3Opaleye Management Inc.720,000-170,000 (-19.10%)1.96%$2 MNov 16, 2026
4Mackenzie Financial Corp528,913-26,763 (-4.82%)1.44%$1 MNov 2, 2026
5Acadian Asset Management LLC459,016+351,713 (+327.78%)1.25%$1 MNov 9, 2026
6Shikiar Asset Management Inc305,4690 (0.00%)0.83%$1 MOct 20, 2026
7Geode Capital Management, LLC285,178-15,343 (-5.11%)0.78%$1 MNov 6, 2026
8Bridgeway Capital Management, LLC227,368+50,000 (+28.19%)0.62%$0 MNov 16, 2026
9Panagora Asset Management Inc226,593+160,568 (+243.19%)0.62%$0 MNov 12, 2026
10BlackRock, Inc.220,714-4,068 (-1.81%)0.60%$0 MNov 13, 2026
11Marshall Wace, LLP215,825New0.59%$0 MNov 13, 2026
12Citadel Advisors LLC169,109+92,044 (+119.44%)0.46%$0 MNov 16, 2026
13Two Sigma Investments, LP148,115-65,671 (-30.72%)0.40%$0 MNov 16, 2026
14Vanguard Fiduciary Trust Co146,608-19,763 (-11.88%)0.40%$0 MNov 13, 2026
15Susquehanna International Group, LLP129,924+82,922 (+176.42%)0.35%$0 MNov 16, 2026
16Jane Street Group, LLC119,491+94,077 (+370.18%)0.32%$0 MNov 12, 2026
17HB Wealth Management, LLC117,925+1,250 (+1.07%)0.32%$0 MOct 23, 2026
18State Street Corp116,801+15,200 (+14.96%)0.32%$0 MNov 12, 2026
19Kestra Advisory Services, LLC102,235-14,000 (-12.04%)0.28%$0 MNov 2, 2026
20XTX Topco Ltd82,493New0.22%$0 MNov 16, 2026
21Northern Trust Corp63,6320 (0.00%)0.17%$0 MNov 16, 2026
22Prelude Capital Management, LLC53,366+11,859 (+28.57%)0.15%$0 MNov 16, 2026
23180 Wealth Advisors, LLC48,200-13,400 (-21.75%)0.13%$0 MNov 3, 2026
24Integrated Wealth Concepts LLC45,2000 (0.00%)0.12%$0 MNov 17, 2026
25UBS Group AG42,407-9,939 (-18.99%)0.12%$0 MNov 10, 2026
Show all 60: investors 26 to 60
Institutional investors 26 to 60 in Fortress Biotech, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26PFG Investments, LLC41,501+5,000 (+13.70%)0.11%$0 MNov 12, 2026
27LPL Financial LLC39,513New0.11%$0 MNov 6, 2026
28Choreo, LLC36,2500 (0.00%)0.10%$0 MOct 28, 2026
29Employees Retirement System of Texas36,127New0.10%$0 MNov 10, 2026
30Provenance Wealth Advisors, LLC33,500New0.09%$0 MOct 30, 2026
31Susquehanna Portfolio Strategies, LLC31,126New0.08%$0 MNov 16, 2026
32Empowered Funds, LLC25,0000 (0.00%)0.07%$0 MNov 13, 2026
33Prudential Financial Inc24,726New0.07%$0 MNov 16, 2026
34Creative Planning21,452New0.06%$0 MNov 2, 2026
35StoneX Group Inc.16,055New0.04%$0 MNov 3, 2026
36Two Sigma Securities, LLC15,383New0.04%$0 MNov 16, 2026
37Corient Private Wealth LP14,9630 (0.00%)0.04%$0 MNov 16, 2026
38Abacus Planning Group, Inc.14,5340 (0.00%)0.04%$0 MNov 2, 2026
39Tower Research Capital LLC (TRC)13,249+11,845 (+843.66%)0.04%$0 MNov 16, 2026
40Universal- Beteiligungs- und Servicegesellschaft mbH13,163New0.04%$0 MNov 10, 2026
41Vanguard Global Advisers, LLC12,5780 (0.00%)0.03%$0 MNov 13, 2026
42SEI Investments Co12,177New0.03%$0 MNov 10, 2026
43Carlson Financial, Inc.12,159-500 (-3.95%)0.03%$0 MNov 5, 2026
44NewEdge Advisors, LLC11,361-3,566 (-23.89%)0.03%$0 MNov 13, 2026
45Spark Investment Management LLC11,100New0.03%$0 MNov 13, 2026
46Osaic Holdings, Inc.10,261+1,200 (+13.24%)0.03%$0 MNov 12, 2026
47Wells Fargo & Company/mn9,167+4,167 (+83.34%)0.02%$0 MNov 16, 2026
48Simplex Trading, LLC8,946-5,562 (-38.34%)0.02%$0 MNov 4, 2026
49Morgan Stanley5,040+1,540 (+44.00%)0.01%$0 MNov 13, 2026
50Rockefeller Capital Management L.P.4,8120 (0.00%)0.01%$0 MNov 13, 2026
51Arax Advisory Partners4,0860 (0.00%)0.01%$0 MNov 12, 2026
52SBI Securities Co., Ltd.3,6500 (0.00%)0.01%$0 MOct 22, 2026
53Highbridge Capital Management LLC3,340New0.01%$0 MNov 16, 2026
54Royal Bank Of Canada1,886+1,161 (+160.14%)0.01%$0 MNov 16, 2026
55FMR LLC910New0.00%$0 MNov 10, 2026
56Jpmorgan Chase & Co3390 (0.00%)0.00%$0 MNov 12, 2026
57Larson Financial Group LLC370 (0.00%)0.00%$0 MNov 5, 2026
58Northwestern Mutual Wealth Management Co330 (0.00%)0.00%$0 MNov 13, 2026
59Barclays PLC8-986 (-99.20%)0.00%$0 MNov 6, 2026
60Caitong International Asset Management Co., Ltd7-37 (-84.09%)0.00%$0 MOct 29, 2026

Mutual funds holding Fortress Biotech, Inc.#

14 funds hold shares worth $4 M. Since their previous reports 8 added shares and 2 sold, buying $0 M net.
Mutual funds holding Fortress Biotech, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.697,802$2 M—<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.279,891$1 M—<0.01%+12%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC131,019$0 M—<0.01%+0.5%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors88,143$0 M—0.02%+43%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC49,359$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC35,874$0 M—<0.01%+11%May 31, 2026
🇺🇸 EA Bridgeway Omni Small-Cap Value ETFEmpowered Funds, LLC d/b/a EA Advisers25,000$0 M—0%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC20,365$0 M—<0.01%+243%May 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.18,051$0 M—<0.01%newJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.10,255$0 M—<0.01%−47%Jun 30, 2026
🇺🇸 Nomura Healthcare FundDelaware Management Company6,666$0 M—<0.01%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC5,933$0 M—<0.01%+23%Jun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC728$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC20$0 M—<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 14 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Fortress Biotech, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
20
since
$2.9 M-$19 K$0Nov 2023: bought $2.9 M (2 trades), sold $0 (0 trades)Nov 23Jan 2024: bought $119 K (1 trades), sold $0 (0 trades)Jan 24May 2024: bought $18 K (1 trades), sold $19 K (1 trades)MayJun 2024: bought $33 K (1 trades), sold $0 (0 trades)JunJul 2024: bought $115 K (4 trades), sold $0 (0 trades)JulSep 2024: bought $1.4 M (1 trades), sold $0 (0 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
Fortress Biotech, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed David JinChief Financial OfficerGrant or award+1,190$1.819$2 K1.65 MForm 4
filed David JinChief Financial OfficerGrant or award+400,000——1.65 MForm 4
filed David JinChief Financial OfficerGrant or award+2,967$2.180$6 K1.25 MForm 4
filed Michael S. WeissExecutive Vice Chairman, DirectorGrant or award+475,424——2.28 MForm 4
filed Lindsay A. RosenwaldPRESIDENT, CEO & CHAIRMAN, Director, 10% ownerGrant or award+475,424——4.59 MForm 4
filed Kevin LorenzDirectorGrant or award+27,322——101,009Form 4
filed Malcolm HoenleinDirectorGrant or award+27,322——115,747Form 4
filed J. Jay LobellDirectorGrant or award+27,322——192,397Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Fortress Biotech, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
4.6 M
14.7% of shares · 23.59 days to cover
Dividend per share, Q3 2024
$0.000
Buybacks, Q3 2021
$0M
Q3 2021
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-14.99 reverse split

Fortress Biotech, Inc. dividends per share by quarter
Dividend, quarterPer share
Q3 2024$0.000
Fortress Biotech, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q3 2021Q3 2021$0M
Q2 2021Q2 2021$0M
Q1 2021Q1 2021$0M
Q4 2020Q4 2020$0M
Q3 2020Q3 2021$0M
Q2 2020Q2 2021$0M
Q1 2020Q1 2021$0.1M
Q3 2018Q3 2018$0M
Q3 2017Q3 2018$0M

Fails to deliver

  • : 35 shares at $2.00
  • : 46 shares at $1.96
  • : 85 shares at $1.93
  • : 88 shares at $1.93
  • : 85 shares at $1.94

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Fortress Biotech, Inc. scorecard#

Passes 14 of the 26 checks that could be worked out: strongest in valuation (4 of 5), weakest in financial health (2 of 6). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation4 of 5
    • ✓P/E below its peers' median0.7×P/E 0.7× against Biotechnology's median of 17.5×.
    • ✓Price to book below its peers' median1.5×Price to book 1.5× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median1.1×Price to sales 1.1× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-109.0%Free cash flow is -109.0% of the market value.
    • ✓Earnings yield above the 10-year Treasury yield151.5%Earnings yield 151.5% against the 10-year Treasury's 5.15% on 2026-11-13.
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth3 of 6
    • ✓Revenue grew in the newest year9.7%Revenue up 9.7% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-5.8%-5.8% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-5.8%-5.8% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-0.07 vs -2.69Diluted EPS -0.07 in fiscal 2025 against -2.69 the year before (report's currency).
    • ✓Net income higher than five years earlier$7 M$7 M in fiscal 2025 against -$47 M in 2020.
    • ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
  • Profitability3 of 5
    • ✓Profitable in the newest year$7 MNet income $7 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-111.0%-111.0% against Biotechnology's median of -60.5% (243 companies).
    • ✓Return on equity above 15%18.8%18.8% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-111.0%-111.0% in fiscal 2025 against -268.8% in 2022.
  • Financial health2 of 6
    • ✓Short-term assets cover short-term liabilities2.5×Current ratio 2.49 at the end of fiscal 2025.
    • ✗Debt below equity1.1×Debt to equity 1.09 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $25 M at the end of fiscal 2025.
    • ✗Operating income covers interest five times-7.0×Operating income -7.0 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-5.61Z-score -5.61 (distress zone) for fiscal 2025.
  • Shareholder returns2 of 4
    • ✓Pays a dividendYesPaid dividends in fiscal 2025.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • ✓Dividends under 75% of net income9.7%Dividends were 9.7% of net income in fiscal 2025.
    • ✗Share count up no more than 2% in a year34.2%Diluted shares up 34.2% in fiscal 2025.
    • ✗Dividends and buybacks above 3% of the market value0.9%Dividends and buybacks were 0.9% of the market value.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Fortress Biotech, Inc.'s statements, beside the median of Biotechnology.

Fortress Biotech, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-111.0%-60.5%
Net margin10.8%-68.9%
Return on equity18.8%-61.0%
Revenue growth, 3 years a year-5.8%12.9%
Revenue growth9.7%15.8%
Debt to equity1.09×0.26×

5of 9on the Piotroski tests of financial strength

  • Only -965% of net income arrived as cash from operations.
  • The share count rose 34.2% in the year.
  • Operating income covers the interest bill only -7.0 times.
  • Receivables grew 191% while revenue grew 10%: customers are paying later, or sales were booked ahead of cash.

Fortress Biotech, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Fortress Biotech, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue635885766946372718816
Cost of revenue212123r313215116.13.70.8r
Research and development1257106135129648187r48r35r
Selling, general and administrative968891r11487615653——
Selling and marketing—————171712105.8
General and administrative—————443842r51r28r
Operating expenses———————147107r82
Total costs and expenses133168227279257140147147——
Operating income−70−110−142−204−189−94−111−120−90r−66
Interest and finance income2.52.73.01.40.61.52.61.10.80.3
Interest expense and finance costs10141512151512—5.93.7
Net interest income——————0.00.00.0—
Other non-operating income (expense)37−10−11−9.924−8.69.2−11−7.7r−5.6
Income before tax−34−121−154−213−164−103−102−131−98r−71
Income tax−0.60.30.50.40.50.5r001.50
Income from discontinued operations——————0−11−2.3—
Net income including minority interests−33−121−154−214−165−103−102−142−100−71
Minority interests' share of net income−40−75−94−127−100−56−62−58−33−16
Net income attributable to shareholders6.8−46−61−87−65−47−40−84−67−55
Earnings per share, basic-0.07-2.69-8.47-15.97r-0.79-0.65-0.73-1.94-1.61-1.38
Earnings per share, diluted-0.07-2.69-8.47-15.97r-0.79-0.65-0.73-1.94-1.61-1.38
Shares, weighted average (basic)28218.15.9r82—————
Shares, weighted average (diluted)28218.15.9r827255434240
Balance sheet
Cash and cash equivalents7957811783062331376695r105r
Short-term investments——————018360
Receivables301015282324r145.57.81.8
Inventory9.61410149.91.40.90.70.20.2
Other current assets4.97.1119.77.16.74.16.75.7r9.1
Current assets12490117230346266r156111183110
Property, plant and equipment2.53.36.513151212127.1r7.4
Right-of-use (leased) assets121417201920210——
Goodwill————————1919
Other intangible assets2832202713157.41.40.9r17
Investments in associates15———————0.30.3
Long-term investments————0181101.41.4
Total assets186144168294397333r226141246171
Accounts payable143235574711r353427r24r
Current liabilities50718512810152r465671r57
Lease liabilities (non-current)131518222123240——
Total liabilities123146166244171136r15412112588
Retained earnings−734−741−695−634−547−483−436−396−312−245
Shareholders' equity50232342109100261.95338
Minority interests12−24−218.31179746186844
Total equity62−1.61.650226197732012183
Total liabilities and equity186144168294397333r226141246171
Shares outstanding3128157.4r1019574585149
Cash-flow statement
Depreciation and amortization————————1.20.9
Share-based compensation293317231913131513r12
Cash from operating activities−66−80−128−179−117−84−95−99−81r−46r
Capital expenditure—0−0.1−2.7−4.6−1.9−2.3−7.1−0.6r−6.4
Intangible assets bought0−15−5.00−0.4−1.2−2.4−1.20−0.4
Acquisitions, net of cash acquired————————−4.6−4.6
Cash from investing activities10−15−2.1−2341−7.22019−40r−6.1
Debt issued———470—————
Debt repaid—0−500−10—————
Shares issued1.03.72.06.19.146r2110—0
Shares bought back—————−0.10———
Dividends paid−0.7−0.7−0.7−0.7−0.7−0.20———
Cash from financing activities7771337514917214751150r43r
Change in cash22−25−98−127738272−2929r−9.0r
Report10-K10-K10-K10-K10-K10-K10-K/A10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Fortress Biotech, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Qbrexza$25 M40%
  • Emrosi$15 M23%
  • Accutane$13 M20%
  • Foam franchise products (Amzeeq & Zilxi)$6 M9.3%
  • Other / legacy product revenue$3 M4.3%

Business segments

  • Journey$62 M98%
  • Avenue$1 M2.2%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Fortress Biotech, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.9 M
Year
Other top executives, average
$1.6 M
the CEO earned 1.9× this
$100 invested is now
—
Fortress Biotech, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Year$2.9 M$3.6 M$1.6 M—
2024Year$1.4 M$808 K$1.9 M—
2023Year$1.1 M−$1.9 M$1.2 M—

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Fortress Biotech, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Acquisition or sale completed 1 · Directors and officers 1 · Material agreement 4 · New debt 2 · Unregistered share sale 2 · Shareholder vote 2 · Results announced 8

Fortress Biotech, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreementNew debt8-K
Material agreementNew debtUnregistered share sale8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Acquisition or sale completed8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Material agreementUnregistered share sale8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Aug 13, 2026

Acquisitions and funding#

5 private funding rounds before listing

Private share sales · funding history

Private share sales of Fortress Biotech, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2017$3 MPrivate placement after listing$2 to $10 million2debt, optionsSEC
May 2011$26 MNo. 5$10 to $50 million344equity, optionsSEC
Jan 2011$14 MNo. 4$10 to $50 million1equitySEC
May 2010$4 MNo. 3$2 to $10 million41equity, optionsSEC
Apr 2010$7 MNo. 2$2 to $10 million25equity, optionsSEC
Jul 2009$1 MNo. 1Under $2 million16debt, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Fortress Biotech, Inc.#

$20 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.

Lobbying, 2025
$20 K
#1,437 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$20 K
  • Health Issues1 report

Lobbying firms hired in 2025

THE VOGEL GROUP $20 K

Fortress Biotech, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$20 K—2
2025$20 K—1

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Fortress Biotech Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

How Fortress Biotech, Inc. compares in Biotechnology

  • Market cap$74 M · higher than 32% of 726
  • Revenue$63 M · higher than 62% of 647
  • Revenue growth9.7% · higher than 53% of 438
  • P/E ratio0.7× · lower than 99% of 100
  • Price / sales1.1× · lower than 92% of 339
  • Price / book1.5× · lower than 68% of 534
  • FCF yield-109.0% · higher than 9% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Fortress Biotech, Inc.🇺🇸$74 M0.7×—+9.7%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
2016
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, Wikidata, value.today research, Wikipedia, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Fortress Biotech, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Fortress Biotech, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Fortress Biotech, Inc.? Suggest a correction